Research Grade Inotuzumabc (DHD38502)
- CAS No.
- 1660159-36-3
- Chemical Name:
- Research Grade Inotuzumabc (DHD38502)
- Synonyms
- Inotuzumab (anti-CD22);Research Grade Inotuzumabc (DHD38502)
- CBNumber:
- CB112402134
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | UC47AV3PU8 |
Research Grade Inotuzumabc (DHD38502) price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620868 | Inotuzumab 97.22% | 1660159-36-3 | 1mg | $303 | 2026-06-04 | Buy |
| ChemScene | CS-0620868 | Inotuzumab 97.22% | 1660159-36-3 | 5mg | $948 | 2026-06-04 | Buy |
| ChemScene | CS-0620868 | Inotuzumab 97.22% | 1660159-36-3 | 10mg | $1517 | 2026-06-04 | Buy |
| ChemScene | CS-0620868 | Inotuzumab 97.22% | 1660159-36-3 | 25mg | $2383 | 2026-06-04 | Buy |
| ApexBio Technology | BA2316 | Inotuzumab | 1660159-36-3 | 1mg | $315 | 2026-05-06 | Buy |
Research Grade Inotuzumabc (DHD38502) Chemical Properties, Uses, Production
Uses
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
in vivo
Inotuzumab ozogamicin (100 μg/kg, i.p., twice a week for 2 weeks) combined with Venetoclax (HY-15531), Dexamethasone (HY-14648) induces long-term survival in murine patient-derived xenograft (PDX) models[3].
Inotuzumab (0.27, 3.2 mg/kg, i.p., a single dose for 400 h) inhibits tumor growth in mouse xenograft models[4].
| Animal Model: | Mouse xenograft models[4]. |
| Dosage: | 0.27, 3.2 mg/kg |
| Administration: | i.p., a single dose for 400 h |
| Result: | Decreased the tumor volume in mouse xenograft models. |
References
[1] Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. DOI:10.1186/s40364-019-0160-4
[2] Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. DOI:10.1182/bloodadvances.2018026211
[3] Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. DOI:10.1182/blood.2020008544
[4] Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. DOI:10.1208/s12248-016-9929-7
Research Grade Inotuzumabc (DHD38502) Preparation Products And Raw materials
Raw materials
Preparation Products
Research Grade Inotuzumabc (DHD38502) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Shanghai Aladdin Biochemical Technology Co.,Ltd. | 6206333 13167063860 | anhua.mao@aladdin-e.com | China | 43601 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Wuhan Maixi Biotechnology Co., Ltd | 18007167883 18007167883 | Service@mabnus.com | China | 921 | 58 |
